Oncolytics Biotech Inc.

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oncology treatments. The company's mission is to extend and improve the lives of cancer patients by pioneering innovative immunotherapy treatments. Headquartered in San Diego, California, since completing its domicile change to the United States in April 2026, Oncolytics also maintains an office in Calgary, Alberta, Canada.

Oncolytics' primary product candidate is pelareorep (formerly REOLYSIN), an intravenously delivered immuno-oncolytic virus. This double-stranded RNA immunotherapeutic agent is designed to induce anti-cancer immune responses by converting immunologically "cold" tumors into "hot" inflamed phenotypes through the activation of both innate and adaptive immune responses. The company focuses on developing pelareorep for various solid tumors and hematological malignancies, with ongoing clinical programs targeting metastatic breast cancer, pancreatic cancer, colorectal cancer, and anal cancer.

Jared Kelly was appointed Chief Executive Officer in June 2025, leading the company's strategic direction. Oncolytics recently completed its domicile change from Canada to the United States, becoming a Nevada corporation with its new headquarters in San Diego as of April 1, 2026. The company's strategy is centered on advancing pelareorep through registration-enabling trials, leveraging its Fast Track designations from the FDA for metastatic pancreatic ductal adenocarcinoma (mPDAC) and metastatic breast cancer, and pursuing a registrational pathway for anal cancer.